Despite the plethora of proposed plasma biomarkers in cardiovascular disease, the clinical value is, for now, largely restricted to the measurement of cardiac troponin and cardiac natriuretic peptides (ANP and BNP). The gene discussed is NPPA; the disease is cardiovascular disorder.